Featured Articles

  • Cell and gene therapy takeaways from ASCO 2026

    Wednesday, June 03, 2026
    The American Society for Clinical Oncology annual meeting never fails to deliver inspiring advances in cancer-care. read more

  • Coexistence, not conflict, in cell therapy platform war

    Wednesday, May 27, 2026
    In theory, in vivo makes other cell therapies obsolete, but a panel at BPI Europe in Vienna last month painted a more measured picture. read more

  • Ten best practices for developing ophthalmic CGTs

    Wednesday, May 20, 2026
    Here are 10 best practices that can help drug developers avoid delays, protect data quality, and meet regulatory, clinical and manufacturing expectations. read more

  • Make drugs, not war

    Friday, May 08, 2026
    Developers who treat China’s rise as a strategic opportunity — both for partnership and as a wakeup call to address inefficiencies in Western systems — will be best positioned to take home the ultimate prize: bringing lifesaving treatments ... read more

  • Container closure integrity in the deep cold

    Wednesday, April 29, 2026
    Robust CCI verification is essential not only for regulatory compliance but also for protecting product stability and patient safety. As advanced therapies become more complex, the rigor and precision of CCI testing will remain ... read more

  • Visible particulates in cell therapy

    Wednesday, April 15, 2026
    The cell therapy sector remains constrained by particulate guidance based on traditional parenteral products, says a BioPhorum publication. read more

  • Navigating material demands of next-gen CGTs

    Wednesday, April 01, 2026
    Cultivating resilient, stage-appropriate supply strategies is an essential yet often overlooked part of delivering safe, effective therapies to patients. read more

  • Electroporation-based delivery for gene editing

    Wednesday, March 25, 2026
    New findings establish the feasibility of combining nonviral ex vivo gene editing, hepatocyte transplantation, and in vivo selection, and support the clinical translation of cell-based gene-editing therapies for inherited metabolic liver ... read more

  • Reaping the spoils of CGT’s golden age

    Tuesday, March 10, 2026
    We are living in the golden age of cell and gene therapy — but the spoils will go to those who chart a deliberate course, choose the right partners, and translate breakthrough science into sustainable commercial reality. read more

  • Preclinical roadmap to first-in-human

    Thursday, March 05, 2026
    A well-designed development roadmap can be a powerful strategic asset — shaping investor confidence and guiding capital deployment. Yet questions persist around the optimal timing for roadmap buildout and how it should evolve alongside ... read more

  • From pirates to powerhouse

    Tuesday, February 24, 2026
    The evolution from imitation to innovation has created an ecosystem designed to reward novel science and transformative treatment approaches — and Swiss companies are now claiming their stake. read more

  • Swimming upstream

    Wednesday, February 18, 2026
    Rare and ultra-rare disease patients have long been forced to struggle upstream. read more
Page